# OnCo record platinum-sensitive-ovarian-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "platinum-sensitive-ovarian-cancer" ;
  schema:name "Platinum-sensitive ovarian cancer"@en ;
  schema:alternateName "Platinum-sensitive relapsed ovarian cancer"@en, "Newly diagnosed ovarian cancer in response to platinum"@en, "Platinum-free interval over six months"@en ;
  schema:description "Platinum-sensitive ovarian cancer is disease that responded to carboplatin and either has not relapsed or relapses more than six months after the last dose. It is treated with further platinum chemotherapy, sometimes repeat surgery, and above all with maintenance PARP inhibitors, which keep BRCA-mutant tumours away for years and have raised long-term survival."@en ;
  schema:url <https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/saruparib/>, <https://onco.cc/targets/atr/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/ideas/idea-ctdna-guided-parp-duration/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/trials/duo-o/> ;
  onco:standardOfCare <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/solo-1/>, <https://onco.cc/trials/paola-1/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/targets/brca/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/paola-1/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/trials/prima/>, <https://onco.cc/technologies/hrd-testing/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/pairings/parp-plus-bevacizumab/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/trials/prima/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/trials/gog-0218-icon7/>, <https://onco.cc/trials/desktop-iii/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pegylated-liposomal-doxorubicin/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/targets/atr/>, <https://onco.cc/targets/wee1/>, <https://onco.cc/trials/athena-mono/> .